QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
NASDAQ:IMCR

Immunocore - IMCR Price Target & Analyst Ratings

$63.30
-0.99 (-1.54%)
(As of 02/6/2023 12:00 AM ET)
Add
Compare
Today's Range
$61.40
$64.63
50-Day Range
$51.43
$64.29
52-Week Range
$21.00
$69.06
Volume
201,205 shs
Average Volume
288,721 shs
Market Capitalization
$2.78 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$78.25

Immunocore Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 9 Analyst Ratings

Consensus Analyst Price Target

$79.13
25.00% Upside
High Prediction$90.00
Average Prediction$79.13
Low Prediction$67.00
TypeCurrent
2/6/22 to 2/6/23
1 Month Ago
1/7/22 to 1/7/23
3 Months Ago
11/8/21 to 11/8/22
1 Year Ago
2/6/21 to 2/6/22
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
7 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$79.13$79.13$76.00$54.75
Predicted Upside25.00% Upside48.26% Upside65.35% Upside18.33% Upside
Get Immunocore Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter.

IMCR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IMCR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Immunocore Stock vs. The Competition

TypeImmunocoreMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.64
2.46
Consensus RatingBuyBuyHold
Predicted Upside25.18% Upside1,832.68% Upside9.37% Upside
News Sentiment RatingPositive News
Neutral News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/16/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$33.00 ➝ $80.00+34.63%
11/30/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$80.00+32.30%
11/21/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Patrick Trucchio
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$80.00 ➝ $90.00+40.17%
11/10/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$72.00 ➝ $79.00+790,000,000.00%
9/14/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$60.00 ➝ $67.00+65.92%
9/8/2022LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$82.00+64.07%
8/8/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
8/8/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$70.00+28.68%
8/2/2022BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$85.00+90.03%
10/19/2021Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$56.00+47.68%
3/2/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$65.00+32.52%
(Data available from 2/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












IMCR Price Target - Frequently Asked Questions

What is Immunocore's consensus rating and price target?

According to the issued ratings of 9 analysts in the last year, the consensus rating for Immunocore stock is Buy based on the current 9 buy ratings for IMCR. The average twelve-month price prediction for Immunocore is $79.13 with a high price target of $90.00 and a low price target of $67.00. Learn more on IMCR's analyst rating history.

Do Wall Street analysts like Immunocore more than its competitors?

Analysts like Immunocore more than other Medical companies. The consensus rating score for Immunocore is 3.00 while the average consensus rating score for medical companies is 2.64. Learn more on how IMCR compares to other companies.

Is Immunocore being upgraded by Wall Street analysts?

Over the previous 90 days, Immunocore's stock had 1 upgrade by analysts.

Does Immunocore's stock price have much upside?

According to analysts, Immunocore's stock has a predicted upside of 48.26% based on their 12-month price targets.

What analysts cover Immunocore?

Immunocore has been rated by Barclays, HC Wainwright, Morgan Stanley, and The Goldman Sachs Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:IMCR) was last updated on 2/6/2023 by MarketBeat.com Staff